|
Tue, 08/24/2021 - 07:06 |
CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors |
CTI BioPharma |
|
Tue, 12/08/2020 - 07:39 |
Asciminib Found Safe and Effective for Hard-to-Treat Chronic Myeloid Leukemia |
American Societ... |
|
Fri, 06/14/2019 - 03:26 |
ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting |
ArQule |
|
Fri, 06/07/2019 - 08:20 |
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA) |
ArQule |
|
Tue, 05/14/2019 - 22:45 |
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis |
Pfizer |
|
Thu, 01/03/2019 - 05:00 |
News / Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata |
Pfizer |
|
Thu, 01/03/2019 - 04:02 |
Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata |
Pfizer |
|
Mon, 11/19/2018 - 04:48 |
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting |
ArQule |
|
Fri, 09/14/2018 - 21:27 |
Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress |
Pfizer |
|
Wed, 09/05/2018 - 11:42 |
Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata |
Pfizer |
|
Fri, 06/15/2018 - 08:14 |
ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531 |
ArQule |
|
Thu, 06/07/2018 - 11:53 |
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA) |
ArQule |
|
Thu, 12/14/2017 - 03:25 |
Pfizer Initiates Phase 3 Program for PF-04965842, a JAK1 Inhibitor in Development for Moderate-to-Severe Atopic Dermatitis |
Pfizer |
|
Thu, 11/30/2017 - 15:49 |
Blocking Gene Expression Improves Outcomes in Blood Disease in Models |
Northwestern Un... |
|
Tue, 07/11/2017 - 07:14 |
ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies |
ArQule |
|
Fri, 06/23/2017 - 11:30 |
ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA) |
ArQule |
|
Thu, 05/18/2017 - 04:12 |
ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA) |
ArQule |
|
Wed, 04/26/2017 - 05:50 |
ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531 |
ArQule |
|
Tue, 04/11/2017 - 07:07 |
ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531 |
ArQule |
|
Tue, 03/28/2017 - 09:14 |
Mayo Clinic researchers identify interaction among proteins that cause cancer cells to metastasize |
Mayo Clinic |
|
Wed, 11/09/2016 - 04:25 |
Behavior of Alzheimer-linked protein is revealed |
FlandersBio |
|
Thu, 02/04/2016 - 07:28 |
ArQule to Present at Upcoming Investor Conferences |
ArQule |
|
Mon, 08/03/2015 - 08:45 |
New insight into how the immune system sounds the alarm |
Salk Institute |
|
Wed, 06/10/2015 - 12:05 |
Scientists Identify 'Mutation Accelerator' in Gene Mutation Linked to Common Adult Leukemia |
Johns Hopkins H... |
